Oak Ridge Investments LLC Decreases Holdings in Blueprint Medicines Co. (NASDAQ:BPMC)

Oak Ridge Investments LLC decreased its position in shares of Blueprint Medicines Co. (NASDAQ:BPMC) by 3.9% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 15,135 shares of the biotechnology company’s stock after selling 609 shares during the period. Oak Ridge Investments LLC’s holdings in Blueprint Medicines were worth $1,400,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently bought and sold shares of BPMC. Susquehanna Fundamental Investments LLC acquired a new position in Blueprint Medicines during the 1st quarter valued at approximately $474,000. Hsbc Holdings PLC acquired a new position in Blueprint Medicines during the 2nd quarter valued at approximately $1,060,000. Comerica Bank increased its stake in shares of Blueprint Medicines by 2,582.9% in the first quarter. Comerica Bank now owns 10,839 shares of the biotechnology company’s stock worth $1,028,000 after acquiring an additional 10,435 shares during the period. Federated Hermes Inc. increased its stake in shares of Blueprint Medicines by 27.8% in the second quarter. Federated Hermes Inc. now owns 62,354 shares of the biotechnology company’s stock worth $6,721,000 after acquiring an additional 13,579 shares during the period. Finally, SG Americas Securities LLC increased its stake in shares of Blueprint Medicines by 82.8% in the second quarter. SG Americas Securities LLC now owns 21,684 shares of the biotechnology company’s stock worth $2,337,000 after acquiring an additional 9,819 shares during the period.

Blueprint Medicines Stock Down 1.9 %

Blueprint Medicines stock opened at $87.51 on Friday. Blueprint Medicines Co. has a 12-month low of $53.73 and a 12-month high of $121.90. The company has a 50-day moving average price of $88.86 and a 200 day moving average price of $98.35. The company has a debt-to-equity ratio of 1.06, a quick ratio of 3.65 and a current ratio of 3.71.

Blueprint Medicines (NASDAQ:BPMC) last released its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported ($0.89) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.97) by $0.08. Blueprint Medicines had a negative net margin of 29.48% and a negative return on equity of 118.86%. The firm had revenue of $128.20 million during the quarter, compared to analysts’ expectations of $127.56 million. During the same period last year, the business earned ($2.20) earnings per share. Blueprint Medicines’s revenue was up 126.5% compared to the same quarter last year. As a group, analysts expect that Blueprint Medicines Co. will post -3.82 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on BPMC. Baird R W upgraded shares of Blueprint Medicines to a “strong-buy” rating in a research note on Friday, August 2nd. Oppenheimer raised their price target on shares of Blueprint Medicines from $114.00 to $125.00 and gave the company an “outperform” rating in a research report on Monday, July 8th. UBS Group initiated coverage on shares of Blueprint Medicines in a research report on Thursday, October 24th. They set a “neutral” rating and a $88.00 price target on the stock. HC Wainwright restated a “buy” rating and set a $135.00 price target on shares of Blueprint Medicines in a research report on Thursday. Finally, StockNews.com lowered shares of Blueprint Medicines from a “hold” rating to a “sell” rating in a research report on Thursday. Two equities research analysts have rated the stock with a sell rating, six have given a hold rating, eleven have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $120.39.

Insider Buying and Selling at Blueprint Medicines

In other Blueprint Medicines news, insider Fouad Namouni sold 3,633 shares of Blueprint Medicines stock in a transaction dated Thursday, October 3rd. The shares were sold at an average price of $89.32, for a total transaction of $324,499.56. Following the completion of the sale, the insider now directly owns 69,070 shares in the company, valued at $6,169,332.40. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other Blueprint Medicines news, insider Philina Lee sold 41,913 shares of Blueprint Medicines stock in a transaction dated Monday, August 5th. The shares were sold at an average price of $93.19, for a total transaction of $3,905,872.47. Following the completion of the sale, the insider now directly owns 34,729 shares in the company, valued at $3,236,395.51. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Fouad Namouni sold 3,633 shares of Blueprint Medicines stock in a transaction dated Thursday, October 3rd. The shares were sold at an average price of $89.32, for a total transaction of $324,499.56. Following the sale, the insider now owns 69,070 shares of the company’s stock, valued at approximately $6,169,332.40. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 4.21% of the company’s stock.

Blueprint Medicines Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.